Tag Archive for: Aboleris Pharma

Anti-CD45RC Abs suppresses the acute immune response by causing the death of harmful CD45RC+ T cells driving (severe) disease in patients. © Aborleris Pharma SA (Zoersel, Nantes
Financing

Aboleris Pharma bags €27.3m in Series A Financing

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

Read more